Mirataz™ is a transdermal ointment containing mirtazapine. It is the first FDA-approved transdermal medication for the management of weight loss in cats.
In clinical studies, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2mg per day
Gives clients a practical way to manage their cat's weight loss without administration of oral medication and does not rely on the cat to eat to be medicated
Mirataz achieves measurable plasma concentrations of mirtazapine in cats using proprietary Accusorb™ technology.
Well tolerated both locally and systemically in clinical studies
View the detailed product information for more detailed information and study reference